CytomX Therapeutics (CTMX) Amortizatization of Intangibles (2014 - 2026)

CytomX Therapeutics has reported Amortizatization of Intangibles for 13 years, with the latest figure at $726000.0 in Q1 2026.

• For the quarter ending Q1 2026, Amortizatization of Intangibles rose 59.91% year-over-year to $726000.0; the trailing twelve-month figure through Mar 2026 stood at $418000.0 (down 25.89% YoY), and the FY2025 full-year result was $146000.0, changed 0.0% from the prior year.
• Amortizatization of Intangibles for Q1 2026 stood at $726000.0, up from -$1.3 million in the prior quarter.
• The five-year high for Amortizatization of Intangibles was $1.9 million in Q3 2023, with the low at -$5.1 million in Q4 2023.
• Historically, Amortizatization of Intangibles has averaged $68823.5 across 5 years, with a median of $37000.0 in 2022.
• The largest YoY upside for Amortizatization of Intangibles was 43225.0% in 2023 against a maximum downside of 101960.0% in 2023.
• CytomX Therapeutics' Amortizatization of Intangibles stood at $5000.0 in 2022, then tumbled by 101960.0% to -$5.1 million in 2023, then surged by 100.73% to $37000.0 in 2024, then sank by 3724.32% to -$1.3 million in 2025, then surged by 154.14% to $726000.0 in 2026.
• The last three Amortizatization of Intangibles figures came in at $726000.0 (Q1 2026), -$1.3 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.